Siplizumab

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]

Siplizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from rat)
TargetCD2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NY (what is this?)  (verify)

References
  1. ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.